Screener
Neuropace, Inc. NPCE EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Neuropace, Inc.’s reported figures.
The source filing: Neuropace, Inc.’s 10-Q, filed August 11, 2026. Open the filing →
- Filed
- Aug 11, 2026, 4:33 PM EDT
- Fiscal quarter
- Q4 FY2030
- Calendar quarter
- Q4 2030
- Accession
- 0001528287-26-000030
FAQ
- What is Neuropace, Inc.'s EBITDA?
- Neuropace, Inc. (NPCE) reported EBITDA of -$5.04M in Q2 2026.
- How has Neuropace, Inc.'s EBITDA changed year-over-year?
- Neuropace, Inc.'s EBITDA increased by 37.7% year-over-year, from -$8.09M to -$5.04M.
- What is the long-term trend for Neuropace, Inc.'s EBITDA?
- Over 4 years (2021 to 2025), Neuropace, Inc.'s EBITDA has grown at a -7.2% compound annual growth rate (CAGR), from -$23.38M to -$17.37M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Neuropace, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude